Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zevra Therapeutics (ZVRA) Receivables - Net (2018 - 2025)

Historic Receivables - Net for Zevra Therapeutics (ZVRA) over the last 8 years, with Q3 2025 value amounting to $16.8 million.

  • Zevra Therapeutics' Receivables - Net rose 11618.74% to $16.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $16.8 million, marking a year-over-year increase of 11618.74%. This contributed to the annual value of $10.5 million for FY2024, which is 3952.35% down from last year.
  • Zevra Therapeutics' Receivables - Net amounted to $16.8 million in Q3 2025, which was up 11618.74% from $18.3 million recorded in Q2 2025.
  • In the past 5 years, Zevra Therapeutics' Receivables - Net ranged from a high of $18.3 million in Q2 2025 and a low of $1.5 million during Q4 2021
  • For the 5-year period, Zevra Therapeutics' Receivables - Net averaged around $8.9 million, with its median value being $8.3 million (2024).
  • Over the last 5 years, Zevra Therapeutics' Receivables - Net had its largest YoY gain of 44312.83% in 2022, and its largest YoY loss of 7064.03% in 2022.
  • Over the past 5 years, Zevra Therapeutics' Receivables - Net (Quarter) stood at $1.5 million in 2021, then soared by 443.13% to $8.3 million in 2022, then soared by 109.39% to $17.4 million in 2023, then crashed by 39.52% to $10.5 million in 2024, then surged by 60.25% to $16.8 million in 2025.
  • Its last three reported values are $16.8 million in Q3 2025, $18.3 million for Q2 2025, and $12.6 million during Q1 2025.